Pipeline

December 22, 2019
Company Drug/Device Medical Condition Status
Meiji Seika Pharma Co. DMB-3115 plaque psoriasis Phase 1 trial initiated in healthy subjects at one site in Europe
Alligator Bioscience ATOR-1017 cancer Phase 1 trial initiated dosing 50 subjects at three sites in Sweden
MODAG anle138b multiple system atrophy and Parkinson’s disease Phase 1 trial initiated enrolling healthy subjects
Chondrial Therapeutics CTI-1601 Friedreich’s Ataxia Phase 1 trial initiated dosing adult subjects over the age of 18 with Friedreich’s Ataxia
NeuClone Pharmaceuticals ustekinumab psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis Phase 1 trial initiated dosing 210 subjects
Arcus Biosciences

Genentech		 AB928, regorafenib, and atezolizumab colorectal and pancreatic cancer Phase 1/1b trial initiated in subjects with breast or ovarian cancer, gastroesophageal or colorectal cancer, lung cancer and advanced malignancies
OBI Pharma OBI-999 cancer Phase 1/2 trial initiated enrolling subjects with solid tumors including gastric, pancreatic, colorectal and esophageal cancer at the University of Texas MD Anderson Cancer Center in Houston, Texas
Zentalis Pharmaceuticals ZN-c3 cancer Phase 1/2 trial initiated dosing two subjects with advanced solid tumors
Akero Therapeutics AKR-001 non-alcoholic steatohepatitis Phase 2 trial initiated enrolled 80 subjects with non-alcoholic steatohepatitis at multiple centers
DiaMedica Therapeutics DM199 chronic kidney disease Phase 2 trial initiated dosing 60 African American subjects with hypertension and chronic kidney disease with IgA nephropathy
Catabasis Pharmaceuticals edasalonexent Duchenne muscular dystrophy Phase 3 trial initiated enrolled 131 boys affected by Duchenne muscular dystrophy ages 4 to 7 with any mutation type whom had not been on steroids for the previous six months at 37 sites in the United States, Canada, Europe, Israel and Australia
Kamada inhaled Alpha-1 Antitrypsin Alpha-1 Antitrypsin Deficiency Phase 3 trial initiated enrolling 250 subjects with AATD and moderate lung disease
Avadel Pharmaceuticals FT218 Narcolepsy Phase 3 trial initiated enrolled 212 subjects with narcolepsy
Mycovia Pharmaceuticals VT-1161 recurrent vulvovaginal candidiasis Phase 3 trial initiated enrolling 200 subjects with recurrent vulvovaginal candidiasis at 51 sites in the U.S.
Calliditas Therapeutics Nefecon IgA nephropathy Phase 3 trial initiated enrolling 200 subjects with IgAN at approximately 140 sites in 19 countries
Innovation Pharmaceuticals Brilacidin ulcerative colitis Clinical Trial Authorization acceptance granted by the MHRA
Pfizer encorafenib in combination with cetuximab colorectal cancer sNDA granted by the FDA
ITF Pharma TIGLUTIK Amyotrophic Lateral Sclerosis sNDA granted by the FDA
Amneal Pharmaceuticals EluRyng generic version of NuvaRing aNDA granted by the FDA
Daré Bioscience DARE-BV1 bacterial vaginosis IND approval granted by the FDA
Zentalis Pharmaceuticals ZN-c3 cancer IND Approval granted by the FDA
Chondrial Therapeutics CTI-1601 Friedreich’s Ataxia Fast-Track Designation and Rare Pediatric Disease Designation granted by the FDA
Salarius Pharmaceuticals seclidemstat Ewing sarcoma Fast Track Designation granted by the FDA
Boston Scientific EXALT Model D single-use duodenoscope Clearance granted by the FDA
Amarin Pharma Vascepa cardiovascular events FDA approval granted
Pfizer Xeljanz ulcerative colitis Approval granted by the FDA

 

Upcoming Events

Featured Products

Featured Stories

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here